Brief Report
Volume 9:2, 2023

Archives of Surgical Oncology

ISSN: 2471-2671 Open Access

FBXO5 as a Promising Therapeutic Target for Gastric Cancer

Luma Zhang*

Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China

Introduction

Gastric cancer is one of the most common types of cancer worldwide, accounting for approximately 8% of all cancer-related deaths. Despite advances in treatment, the prognosis for patients with advanced gastric cancer remains poor. Thus, there is a pressing need to identify new therapeutic targets for this deadly disease. In recent years, bioinformatics and tissue microarray analyses have emerged as powerful tools for identifying potential therapeutic targets in cancer. In this study, we used these techniques to identify FBXO5 as a promising therapeutic target for gastric cancer. FBXO5 is a member of the F-box protein family, which plays a critical role in the regulation of the cell cycle, cell proliferation and apoptosis. Although previous studies have suggested that FBXO5 may be involved in cancer progression, its role in gastric cancer has not been fully elucidated. To investigate the role of FBXO5 in gastric cancer, we first performed bioinformatics analyses using publicly available databases, including The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Our analysis revealed that FBXO5 expression was significantly upregulated in gastric cancer tissues compared to normal tissues [1].

Description

To confirm these findings, we then performed tissue microarray analyses using samples from patients with gastric cancer. Consistent with our bioinformatics analyses, we found that FBXO5 expression was significantly higher in gastric cancer tissues than in adjacent normal tissues. Importantly, our study also showed, for the first time, that FBXO5 contributes to tumor cell proliferation, clone formation, invasion and migration in gastric cancer. To further explore the underlying mechanisms by which FBXO5 promotes tumor progression in gastric cancer, we examined its effects on the cell cycle. Our results showed that overexpression of FBXO5 promoted the transition of the cell cycle from the G0/G1 to the G2/M phase. This is consistent with previous studies showing that FBXO5 regulates the G2/M checkpoint in the cell cycle. Thus, our findings suggest that FBXO5 may promote gastric cancer progression by regulating the cell cycle [2].

We investigated the relationship between FBXO5 and the tumor microenvironment. Our results showed that FBXO5 expression was negatively related to immune activation, suggesting that FBXO5 may contribute to immune evasion in gastric cancer. Our study identifies FBXO5 as a promising therapeutic target for gastric cancer. Our findings suggest that FBXO5 promotes tumor progression by regulating the cell cycle and may contribute to immune evasion in gastric cancer. Future studies are needed to further explore the underlying mechanisms by which FBXO5 promotes tumor progression and to evaluate the therapeutic potential of targeting FBXO5 in gastric cancer [3].

Gastric cancer is a deadly disease that is characterized by the growth and spread of malignant cells in the stomach. Despite advances in treatment, the prognosis for patients with advanced gastric cancer remains poor. Thus, there is a pressing need to identify new therapeutic targets for this devastating disease. In recent years, researchers have focused on the Tumor Microenvironment (TME) as a promising target for cancer treatment. In this context, FBXO5 has emerged as a potential target for gastric cancer treatment due to its involvement in the TME and its negative relationship with immune activation. FBXO5 is a member of the F-box protein family, which plays a critical role in the regulation of the cell cycle, cell proliferation and apoptosis. Previous studies have suggested that FBXO5 may be involved in cancer progression. However, its role in the TME has not been fully elucidated. To investigate the relationship between FBXO5 and the TME in gastric cancer, researchers have used a variety of techniques, including gene expression profiling, immunohistochemistry and functional assays [4].

Gene expression profiling studies have shown that FBXO5 is differentially expressed in gastric cancer tissues compared to normal tissues. Specifically, FBXO5 expression is upregulated in gastric cancer tissues and is associated with poor prognosis in patients with gastric cancer. Immunohistochemistry studies have also confirmed the upregulation of FBXO5 in gastric cancer tissues and have shown that FBXO5 is primarily expressed in tumor cells rather than in normal cells. Functional assays have further demonstrated that FBXO5 promotes tumor cell proliferation, clone formation, invasion and migration in gastric cancer. One of the most intriguing findings from these studies is the negative relationship between FBXO5 expression and immune activation in gastric cancer. This suggests that FBXO5 may contribute to immune evasion in the TME, which is a major mechanism by which cancer cells evade the immune system and promote tumor growth. Specifically, FBXO5 may inhibit the activation and function of immune cells such as T cells and Natural Killer (NK) cells, which are important for killing cancer cells [5].

Conclusion

Based on these findings, FBXO5 is expected to be a potential target for gastric cancer treatment. Inhibition of FBXO5 may have two beneficial effects: (1) it may directly inhibit tumor cell proliferation, invasion and migration and (2) it may enhance immune activation in the TME, leading to the killing of cancer cells by immune cells. However, further studies are needed to evaluate the therapeutic potential of targeting FBXO5 in gastric cancer and to determine the optimal therapeutic strategies. FBXO5 is an important regulator of the TME in gastric cancer and is negatively related to immune activation. Targeting FBXO5 may be a promising strategy for gastric cancer treatment by inhibiting tumor cell proliferation, invasion and migration and enhancing immune activation in the TME. Further research is needed to fully elucidate the mechanisms by which FBXO5 regulates the TME and to develop effective therapeutic strategies based on FBXO5 inhibition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Smyth, Elizabeth C, Magnus Nilsson, Heike I. Grabsch and Nicole CT van Grieken, et al. "Gastric cancer." *Lancet* 396 (2020): 635-648.
2. Ushijima, Toshikazu and Mitsuru Sasako. "Focus on gastric cancer." *Cancer cell* 5 (2004): 121-125.
3. Crew, Katherine D and Alfred I. Neugut. "Epidemiology of gastric cancer." *WJG* 12

***Address for Correspondence:** Luma Zhang, Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China, E-mail: lumazhang@gmail.com*

Received: 29 March, 2023, Manuscript No. aso-23-98376; **Editor assigned:** 01 April, 2023, PreQC No. P-98376; **Reviewed:** 17 April, 2023, QC No. Q-98376; **Revised:** 22 April, 2023, Manuscript No. R-98376; **Published:** 29 April, 2023, DOI: 10.37421/2471-2671.2023.9.37

(2006): 354.

4. Hallissey, M. T, W. H. Allum, A. J. Jewkes and D. J. Ellis, et al. "Early detection of gastric cancer." *BMJ* 301 (1990): 513-515.

5. Thrift, Aaron P and Hashem B. El-Serag. "Burden of gastric cancer." *CGH* 18 (2020): 534-542.

How to cite this article: Zhang, Luma. "FBXO5 as a Promising Therapeutic Target for Gastric Cancer." *Arch Surg Oncol* 09 (2023): 37.